INS and type 2 diabetes mellitus: Therefore, compared toTZDs, glucose-lowering, insulin-sensitizing agents currently usedfor the treatment of insulin resistance and type 2 diabetes, therexinoids, with further development, may eventually offer theadvantage of promoting weight loss, though being weight-neutralwould be an advantage over TZDs.